Menu
Recruiting NCT07025031

Fetal Growth Restriction a Case Control Study

— Observational Idiopathic Fetal Growth Restriction

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Idiopathic Fetal Growth Restriction. Basic parameters: from 19 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Malaysia
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Maternal Serum Progesterone And Placental Heme Oxgenase-1 Expression In Early Onset Idiopathic Fetal Growth Restriction: A Case Control Study

Overview

The study aims to investigate the responsible factors that leads to idiopathic fetal growth restriction.

Detailed description

The study aims to investigate the relationship between maternal serum level of progesterone, immune-expression of HMOX-1 a placental angiogenesis marker with idiopathic fetal growth restriction.

Primary outcome measures

  • Maternal serum level of progesterone [Time frame: At the point of recruitment from 24 until 32 weeks gestation.]
  • Placental immunoexpression of Heme Oxygenase 1 [Time frame: At delivery within 24 until 38 weeks gestation.]
Secondary outcome measures (1)
  • Placenta histopathology examination [Time frame: At delivery within 24 until 38 weeks gestation]

Eligibility criteria

Inclusion criteria

  • singleton
  • dated pregnancy

Exclusion criteria

  • fetus with structural or chromosomal anomaly
  • receive treatments such as aspirin, progestogen, low molecular weight heparin
  • has pre-existing medical disorders such as autoimmune disease, hypertension, diabetes
  • smoking
  • suspected intrauterine infection

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Observational model
Case-control

Study locations

Malaysia · 2 centers
  • Hospital Canselor Tuanku Muhriz — Kuala Lumpur
  • Hospital Canselor Tuanku Muhriz — Kuala Lumpur

Identifiers

NCT: NCT07025031 · JEP-2025-183

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗